Two severe cases of hypoparathyroidism were associated with two newly identified mutations in the glial cell missing homolog 2 (GCM2) gene by scientists in India. “This report demonstrates the critical role of GCM2 activity in human parathyroid gland development through clinical and genetic analysis of 2 patients with hypoparathyroidism,” the…
Treatment with radioiodine extended the recovery of parathyroid function in patients who underwent surgical thyroid removal, in some cases beyond one year, a study in China has found. Although some studies suggest that hypoparathyroidism might be permanent if it lasts more than six months, this diagnosis “should be cautiously made…
People with chronic hypoparathyroidism and blood calcium levels outside the reference range may have higher odds of developing chronic kidney disease, according to a study. The study, “Association of calcium and phosphate levels with incident chronic kidney disease in patients with hypoparathyroidism: a retrospective case-control study, was…
Amolyt Pharma has raised €130 million (roughly $138 million) to support the clinical development of eneboparatide, previously AZP-3601, the company’s experimental therapy for hypoparathyroidism. The funding will be used in Phase 3 testing of the treatment and will also help develop AZP-3813 for acromegaly, which occurs when…
Online enrollment of an expanded access program for TransCon PTH, an experimental hormone replacement therapy for hypoparathyroidism, is now open to physicians who want to access the therapy for their patients, the treatment’s developer Ascendis Pharma has announced. Ascendis announced last month that the U.S. Food…
Central lymph node dissection, or the removal of lymph nodes in the neck, increases the risk of both temporary and permanent post-surgical hypoparathyroidism in people with thyroid cancer who undergo surgery to remove the thyroid gland, a 10-year French study reports Also, lateral lymph node dissection along with total…
The U.S. Food and Drug Administration (FDA) has greenlit an expanded access program (EAP) for Ascendis Pharma to allow certain adults with hypoparathyroidism to receive TransCon PTH, an investigational parathyroid hormone (PTH) replacement therapy. An EAP allows patients with life-threatening or serious diseases access to investigational therapies…
People who go on to develop hypoparathyroidism after surgery in the neck feel more tired and have less energy than control patients who do not develop the disease, a study from the U.K. has found. However, fatigue and low energy do not appear to reduce overall quality of life,…
Hypoparathyroidism was associated with hypertrophic cardiomyopathy — heart disease marked by thickened heart muscle, so that the heart pumps blood less effectively — in a 73-year-old woman, according to a case study. This rare finding was reported in “Hypertrophic cardiomyopathy in a patient with secondary hypoparathyroidism:…
Ascendis Pharma is seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism in the European Union, the company has announced. The request, submitted as a marketing authorization application (MAA) to the European Medicines Agency (EMA), follows a similar application submitted in September to the U.S.
Get regular updates to your inbox.
